KDEV Karolinska Development AB

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition presents recent preclinical data showing that golexanolone reverses dopamine loss and sustains improvements of Parkinsonian symptoms at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) 2025, in Vienna, Austria, April 1–5th.

Parkinson’s disease is a progressive neurodegenerative disease hallmarked by motor symptoms and disrupted cognitive functions as well as mental health. The disorder is caused by the loss of nerve cells in the brain that produce the signaling substance dopamine, which leads to various symptoms reducing the patient’s well-being and quality of life.

Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms. The company's drug candidate golexanolone has recently shown to improve mechanisms in the midbrain important for brain functions such as motor and cognitive behaviors that leads to dopamine loss and Parkinsonian deficits in a preclinical study in a well-established laboratory model of Parkinson’s disease.

The results from the study increase the understanding of golexanolone’s mechanism of action and support further development of the drug candidate as a potential treatment for Parkinson’s disease.

An abstract summarizing the company’s study has been accepted for presentation at the on-site paper poster session “Alpha-Synucleinopathies, Therapeutic Targets, Mechanisms for Treatment” on Friday, April 4th, as well as at the oral ePoster presentation, a virtual format for digital meeting attendees.

Karolinska Development's ownership in Umecrine Cognition amounts to 73%.



For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:  

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB

Phone: +46 70 207 48 26, e-mail:



TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit .

Attachment



EN
01/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE

Karolinska Development portfolio company OssDsign will change CEO duri...

Karolinska Development portfolio company OssDsign will change CEO during second half of 2025 STOCKHOLM, SWEDEN, April 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has notified a change of CEO during the second half of 2025. The purpose is to support the establishment of leadership with an even stronger presence and focus on the US market. OssDsign launched OssDsign Catalyst in the U.S. in August 2021. Since then, the company has undergone a strategic shift to become a pure-play orthobiologics company and has shown high double-di...

 PRESS RELEASE

Karolinska Developments portföljbolag OssDsign byter vd under andra ha...

Karolinska Developments portföljbolag OssDsign byter vd under andra halvan av 2025 STOCKHOLM, SVERIGE 30 april 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign annonserat ett vd-skifte under andra halvan av 2025. Syftet är att möjliggöra upprättandet av en ledning med större närvaro och fokus på USA-marknaden. OssDsign lanserade i augusti 2021 OssDsign Catalyst i USA. Sedan dess har bolaget genomgått ett strategiskt skifte till att bli ett renodlat ortobiologiföretag och visat kraftig tvåsiffrig tillväxt. OssDsigns styrelse och vd Morten Hennev...

 PRESS RELEASE

Interim Report - January-March 2025

Interim Report - January-March 2025 STOCKHOLM – 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website. “Developmental intensity levels remain high in our portfolio companies, many of which have progressed their positions during the first quarter of the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarter The portfolio company AnaCardio secured SEK 205 million in a series A extension financing round and reported positive r...

 PRESS RELEASE

Delårsrapport för januari – mars 2025

Delårsrapport för januari – mars 2025 STOCKHOLM – den 30 april 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2025. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Intensiteten i utvecklingen som sker i våra portföljbolag är fortsatt hög och flera bolag har flyttat fram sina positioner under årets första kvartal”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget AnaCardio säkrade finansiering om SEK 205 miljoner i en utökad serie A-finansieringsrunda. Bolag...

 PRESS RELEASE

Notice of Annual General Meeting in Karolinska Development AB (publ)

Notice of Annual General Meeting in Karolinska Development AB (publ) The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Annual General Meeting, on Thursday May 15, 2025, at 3:00 p.m. (CEST), at Nanna Svartz väg 2, 171 65 Solna, Sweden. The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders may choose to exercise their voting rights at the AGM by...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch